News

The FDA has extended the action date for its review of Cephalon’s supplemental New Drug Application (sNDA) for Nuvigil (armodafinil) tablets [C-IV], to March 29, 2010. The sNDA

Actelion has said that the first phase III study with Almorexant (Restora 1) has met its primary endpoint – superiority of the dual orexin receptor antagonist Almorexant compared

The Swedish Medical Products Agency has now approved Xerclear for treatment of cold sores. It is a topical treatment that has been demonstrated to prevent the incidence of

Radient Pharmaceuticals (Radient) has signed a three-year marketing, sales and distribution agreement with GenWay Biotech. As per the agreement, GenWay Biotech has non-exclusive rights to distribute RPC’s Onko-Sure

Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries: Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies will launch the

China Aoxing Pharmaceutical (China Aoxing) has received the Good Manufacturing Practice (GMP) re-certification of four dosage forms, including capsule, tablet, granule and oral solution formulations, at its new

The FDA has granted Emergency Use Authorisation (EUA) to TessArae for its TessArray Resequencing Influenza A Microarray Detection Panel for the detection of the 2009 H1N1 Influenza A

The Society of Chemical Manufacturers and Affiliates (SOCMA) has reported that Larry Brotherton, CEO and owner of Ortec was elected Board of Governors chairman during SOCMA’s Annual Meeting

Isis will receive a $10m payment from OncoGenex Pharmaceuticals as a result of OncoGenex’ license of OGX-011 to Teva. OGX-011 is an antisense drug co-discovered by Isis and